Given our focus on identifying an approach with potentially broad activity in multiple sarcoma subtypes, we focused upon cell lines in which we have published data [61] showing EGFR overexpression, supported by the clinical results from two cohorts of tumour samples from patients with soft tissue sarcomas [9, 18] that found EGFR was overexpressed by 78% of the samples across different subtypes of STS. Here, EGFR is linked to sarcoma.